newsfilter
← Latest News
GlobeNewswire·

Rubenstein Public Relations Named Agency of Record for OS Therapies

OSTX
  • Rubenstein Public Relations (RPR) has been named Agency of Record for OS Therapies, Inc. (NYSE: OSTX).
  • OS Therapies achieved critical market entry access via the U.K. Medicines and Healthcare products Regulatory Agency (MHRA) to the national patient registry and Clinical Practice Research Datalink.
  • OS Therapies was previously accepted into the FDA's Project Orbis, a program where 29 MHRA-led oncology products have received approval.
  • RPR will execute a comprehensive communications campaign to guide corporate messaging & brand positioning for OS Therapies in U.S. & global markets.
  • OS Therapies is a clinical-stage oncology company specializing in gene-edited, Listeria-based immunotherapies for Osteosarcoma & other solid tumors.
  • The company's lead asset, OST-HER2, utilizes Listeria bacteria to trigger immune responses against HER2 protein epitopes & holds Orphan Drug, Fast Track, & Rare Pediatric Disease Designations from the FDA.
  • OST-HER2 demonstrated clinically significant benefits in Phase 2b trials regarding event-free survival & overall survival in pulmonary metastatic osteosarcoma.
  • OS Therapies plans to submit a Biologics License Application to the FDA for OST-HER2 in 2026, potentially enabling eligibility for a Priority Review Voucher.
  • The company anticipates submitting Conditional Marketing Authorization Applications to the MHRA & EMA for OST-HER2 in 2026.
  • OST-HER2 received conditional approval from the U.S. Department of Agriculture for treating canine osteosarcoma & completed Phase 1 studies in breast cancer.
  • OS Therapies is advancing next-generation tunable Antibody Drug Conjugates (tADCs) featuring proprietary silicon Si-Linker & Conditionally Active Payload technology.
  • RPR is an award-winning strategic communications firm led by Richard Rubenstein, serving sectors including healthcare, life sciences, & technology.